Weakness Seen in La Jolla Pharmaceutical (LJPC): Stock Tumbles 17.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 7:41AM CST
La Jolla Pharmaceutical aw a big move last session, as the company’s shares fell by nearly 18% which reversed the trend for the company.
LJPC: 16.35 (-0.10), ARQL: 1.15 (+0.01)
Insider Buys And Sells: American Homes 4 Rent, Western Gas Partners
Asif Suria - at Seeking Alpha - Mon Dec 22, 3:50PM CST
Welcome to edition 235 of Insider Weekends. The prolific buying by insiders of energy companies lost some steam last week even as oil and energy stocks rebounded sharply along with the rest of the market. With the S&P 500 closing less than 5...
RH: 96.97 (-0.16), AMH: 17.34 (-0.07), VRTX: 115.15 (+1.40), CODI: 15.99 (-0.11), RES: 13.26 (-0.35), LJPC: 16.35 (-0.10), ICE: 221.73 (-1.70), WES: 73.08 (-0.25), ENH: 59.60 (-0.55), GHC: 877.19 (-0.76)
The 2015 Calendar Of NASH Trial Catalysts II: Galectin Therapeutics And La Jolla Pharmaceutical Co.
Clinically Sound Investor - at Seeking Alpha - Fri Dec 19, 6:37AM CST
LJPC: 16.35 (-0.10), GALT: 3.19 (-0.04)
La Jolla up on angiotensin IP deal
Seeking Alpha - at Seeking Alpha - Tue Dec 16, 11:58AM CST
LJPC: 16.35 (-0.10)
How La Jolla Pharmaceutical (LJPC) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 7:43AM CST
La Jolla Pharmaceutical is one stock that might be an intriguing choice for investors right now as it is seeing solid earnings estimate revision and has a Zacks Industry Rank of 72
LJPC: 16.35 (-0.10)
InsiderInsights.com Daily Round Up 12/15/14: NS, FCX, LJPC, OAS
InsiderInsights - at Seeking Alpha - Tue Dec 16, 2:28AM CST
VR: 41.51 (+0.19), GMCR: 137.65 (+1.10), LJPC: 16.35 (-0.10), FCX: 22.91 (+0.07), NS: 57.17 (+0.24), OSIS: 71.75 (+0.12), SNI: 78.54 (+0.85), GOOG: 528.77 (-1.82), HAIN: 117.25 (+0.23), WIW: 11.28 (+0.03), IDRA: 3.89 (+0.02), VRNS: 32.05 (+1.11), WRLD: 79.98 (+0.15), SNPS: 43.99 (+0.01), AI: 27.70 (-0.12), JGW: 10.70 (+0.04), OAS: 16.66 (-1.05), WIA: 11.55 (+0.06), CRM: 60.33 (-0.17)
La Jolla Pharmaceutical (LJPC) Jumps: Stock Gains 5.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 8:11AM CST
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares rise roughly 6% on the day.
ACRX: 6.61 (+0.06), LCI: 42.29 (+1.79), LJPC: 16.35 (-0.10), IG: 9.11 (-0.01)
La Jolla Pharmaceutical Company and the George Washington University Announce Exclusive Worldwide License Agreement
Business Wire - Tue Dec 09, 3:01PM CST
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, and the George Washington University (GW), today announced that La Jolla and GW have entered into an exclusive worldwide license agreement for GW intellectual property rights covering the use of angiotensin II for the therapeutic treatment of patients with hypotension and shock. La Jolla plans to initiate a phase 3 registration program of LJPC-501, La Jolla's proprietary formulation of angiotensin II, in catecholamine-resistant hypotension (CRH) in the first quarter of 2015.
LJPC: 16.35 (-0.10)
LaJolla down on clinical trial results
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 3:10PM CST
LJPC: 16.35 (-0.10)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 11:48AM CST
IMDZ: 34.96 (+0.78), VTNR: 3.32 (-0.08), CYBR: 41.60 (+0.59), LJPC: 16.35 (-0.10), ZAZA: 3.20 (+0.70), XPLR: 6.60 (+0.06), FUEL: 17.08 (-0.12), NADL: 1.68 (-0.08), DWA: 22.72 (+0.05), CZR: 15.44 (+0.20), RCAP: 11.23 (+0.26), AMTX: 6.25 (-0.25), FLML: 17.01 (-0.98), AMOT: 23.01 (+0.35), RVNC: 16.65 (+0.42), LOCM: 1.15 (+0.03), JGW: 10.70 (+0.04), ICLD: 3.00 (-0.02), VPCO: 1.30 (-0.01), CSH: 22.16 (-0.46)
La Jolla Pharma -12.5% AH after Q3 report, Phase 2 study results
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 5:00PM CST
LJPC: 16.35 (-0.10)
La Jolla Pharmaceutical posts 3Q loss
Automated Insights - Wed Nov 12, 4:06PM CST
SAN DIEGO (AP) _ La Jolla Pharmaceutical Co. (LJPC) on Wednesday reported a loss of $5.1 million, or 37 cents per share, in its third quarter.
LJPC: 16.35 (-0.10)
La Jolla Pharmaceutical misses by $0.06
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 3:39PM CST
LJPC: 16.35 (-0.10)
Results from Phase 2 Study of GCS-100 in Chronic Kidney Disease Being Presented at American Society of Nephrology Kidney Week
Business Wire - Wed Nov 12, 3:14PM CST
--Improvement More Pronounced in Diabetic Patients
LJPC: 16.35 (-0.10)
La Jolla Pharmaceutical Company Announces Third Quarter and Year-to-Date 2014 Financial Results and Corporate Highlights
Business Wire - Wed Nov 12, 3:02PM CST
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported third quarter and year-to-date 2014 financial results and highlighted recent corporate progress and near-term milestones.
LJPC: 16.35 (-0.10)
La Jolla Pharmaceutical (LJPC) in Focus: Stock Surges 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:44AM CST
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares surge over 10% on the day
ENDP: 72.10 (+0.34), LCI: 42.29 (+1.79), BCRX: 11.83 (+0.76), LJPC: 16.35 (-0.10)
La Jolla Pharmaceutical Co. (LJPC) Jumps: Stock Rises 10.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 8:32AM CDT
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares rise more than 10% on the day.
LJPC: 16.35 (-0.10), CEMP: 20.66 (+0.78), IG: 9.11 (-0.01), BIOD: 1.36 (-0.04)
5 Stocks Spiking on Unusual Volume
at The Street - Mon Oct 27, 6:00AM CDT
Keep these stocks trading on unusual volume on your trading radar.
SUSP: 46.00 (+0.69), LJPC: 16.35 (-0.10), IPCM: 45.95 (-0.19), EGBN: 35.96 (+0.12), CSL: 91.36 (+0.04)
La Jolla Pharmaceutical Company Announces Data Presentation at the American Society of Nephrology Kidney Week
Business Wire - Thu Oct 23, 3:01PM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) ("the Company" or "La Jolla"
LJPC: 16.35 (-0.10)
La Jolla (LJPC) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 9:41AM CDT
La Jolla (LJPC) Shares March Higher, Can It Continue?
LJPC: 16.35 (-0.10)